AstraZeneca buys CinCor Pharma for $1.8 billion

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, an American biopharmaceutical company at the clinical stage of development. CinCor Pharma is developing new treatments for resistant and uncontrolled hypertension, as well as chronic kidney disease. The deal will amount to $1.8 billion.